Giredestrant Yields Lower Treatment Discontinuation vs SOC

In an interview with Targeted Oncology at the San Antonio Breast Cancer Symposium (SABCS), Aditya Bardia, MD, MPH, FASCO, discussed the results of the phase 3 lidERA trial (NCT04961996), examining giredestrant (GDC-9545) vs standard-of-care (SOC) endocrine therapy in patients with estrogen receptor-positive, HER2-negative, medium- and high-risk early breast cancer.

Bardia, a professor in the Department of Medicine, Division of Hematology/Oncology and director of Translational Research Integration at the University of California, Los Angeles Health explained that giredestrant significantly improved invasive disease-free survival (IDFS) compared to the SOC. Three-year IDFS rates were 92.4% for giredestrant vs 89.6% for SOC.

Watch part one of the interview here.